Comparative Pharmacology
Head-to-head clinical analysis: RAPIVAB versus TAMIFLU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAPIVAB versus TAMIFLU.
RAPIVAB vs TAMIFLU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neuraminidase inhibitor; inhibits influenza virus neuraminidase, preventing viral replication and release from infected cells.
Oseltamivir phosphate is a prodrug that is hydrolyzed to the active metabolite oseltamivir carboxylate, a selective inhibitor of influenza virus neuraminidase, an enzyme required for viral replication and release from infected cells.
200 mg IV as a single dose infused over 30 minutes.
75 mg orally twice daily for 5 days
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours in healthy adults; prolonged in renal impairment (up to 40-60 hours in severe cases), supporting once-daily dosing.
Terminal elimination half-life of oseltamivir carboxylate is 4.4 hours (range 3.9–5.0 h) in healthy adults, allowing twice-daily dosing; prolonged to 18–24 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal as unchanged drug via glomerular filtration and tubular secretion; ~70% excreted unchanged in urine over 24 hours, with ~30% undergoing hepatic metabolism via glucuronidation followed by biliary excretion.
Renal excretion of the active metabolite oseltamivir carboxylate accounts for >90% of absorbed drug via glomerular filtration and tubular secretion; <1% excreted as parent oseltamivir in urine; fecal elimination <5%.
Category C
Category C
Neuraminidase Inhibitor
Neuraminidase Inhibitor